This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
by Sweta Killa
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
UnitedHealth Rises on Q1 Earnings Beat: ETFs to Gain
by Sweta Killa
UnitedHealth Group (UNH) breezed past the Zacks Consensus Estimate on both earnings and revenues.
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
by Sanghamitra Saha
At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Buffett's Wisdom: 6 ETF Strategies for Investors
by Sanghamitra Saha
Follow Warren Buffett's latest tips and bet on these ETFs.
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
by Sweta Killa
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
UnitedHealth Beats on Q4 Earnings, Shares Slip: ETFs in Focus
by Sweta Killa
The largest U.S. health insurer UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2023 results but medical costs rose more than expected for the first time in two years.
Healthcare ETFs Start 2024 on a Positive Note
by Sweta Killa
After underperforming in 2023, the healthcare sector seems to be back on track at the start of the New Year. Healthcare generally outperforms during periods of low growth and high uncertainty.
ETFs to Secure Your Portfolio Amid Potential Economic Fluctuations
by Yashwardhan Jain
The possibility of a mild recession, rising fears of an economic slowdown and significant debt levels are some possible headwinds that could dampen the prospects of the economy in 2024. Look into funds to benefit from such a situation.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
by Sweta Killa
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus
by Sweta Killa
The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.
UnitedHealth Beats on Q3 Earnings, Raises View: ETFs to Gain
by Sweta Killa
UnitedHealth (UNH) reported better-than-expected third-quarter 2023 results. Earnings and revenues breezed past the Zacks Consensus Estimate. The company also lifted the lower end of its full-year earnings guidance.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
by Sweta Killa
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
5 ETFs to Buy on JNJ's Q2 Earnings Strength
by Sweta Killa
Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
UnitedHealth Beats Q2 Earnings, Updates View: ETFs to Gain
by Sweta Killa
UnitedHealth (UNH) reported better-than-expected second-quarter 2023 results, breezing past the Zacks Consensus Estimate for earnings and revenues. The company lifted the lower end of its full-year earnings guidance.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
The Zacks Analyst Blog Highlights XHB, FXR, XLP and IYH
by Zacks Equity Research
XHB, FXR, XLP and IYH are part of the Zacks top Analyst Blog.
4 Top-Ranked Sector ETFs to Buy in the Second Half
by Sweta Killa
Investors could be well served by ETFs from sectors that house the top-ranked industries.
The Zacks Analyst Blog Highlights VYM, SPYD, IYH, XLP and FTCS
by Zacks Equity Research
VYM, SPYD, IYH, XLP and FTCS are part of the Zacks top Analyst Blog.
5 ETF Underdogs of 1H Likely to Turnaround in 2H
by Sanghamitra Saha
The Wall Street rally in the first half of 2023 involved a narrow market breadth. Hence, there were many ETF under-performers. But these ETFs could rebound in the second half.